Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Time Finance makes strong start after record year

(Sharecast News) - AIM-listed finance provider Time Finance has reported a strong start to the new financial year following a record 12 months to 31 May, with annual profits surging by a third. Full-year revenues were up 12% at £37.1m, with 31% growth seen in the 'hard' subset of asset finance to £111m and 8% growth in the invoice finance division to £70m.

Deal origination improved 5% to £96.5m, while the lending book expanded 5% to £96.5m.

That helped pre-tax profits jump 34% to £7.9m, while earnings per share rose 31% to 6.3p.

"Our strong financial performance reflects the strategic decision to pursue growth through aggressive own book lending targets. This is facilitated by utilising our available cash resources to leverage our funding facilities to maximum effect," said non-exec chair Tanya Raynes.

Since the year-end, results have been ahead of management's initial projections, Time Finance said, with full-year results expected to be "at least in line with market expectations".

Revenues in the three months to 31 August were up a further 3% to a quarterly record of £9.4m, as the gross lending book reached an all-time high of £221.1m. First-quarter profits were 11% higher at £2.1m.

"The lending book has now seen consistent increases for seventeen consecutive quarters, reflecting the demand for our multi-product offering and the value that is placed on our first-class customer service by UK businesses seeking access to finance," said chief executive Ed Rimmer.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.